Shermaine Tiley is a founding managing partner at CTI Life Sciences Fund who combines a decade of experience as an NIH SBIR consultant in immunology and infectious disease with deep HIV and viral immunology research background, including authorship on HIV neutralization studies. She bridges Canadian and U.S. biotech ecosystems through her cross-border education and experience, from her Johns Hopkins PhD and New York faculty roles to her MBA from University of Toronto and senior investing position at Drug Royalty on Bay Street.